Laboratory studies with BL-S 578 (Cefadroxil) a new broad-spectrum orally active cephalosporin.
BL-S 578 (Cefadroxil) is a new orally active semisynthetic cephalosporin antibiotic with broad-spectrum antibacterial activity. The new compound was evaluated in vitro in comparison with cephalexin. Some properties studies such as, antibacterial activity, binding with serum proteins and stability in acid and neutral solution at 37 degrees C for both cephalosporins were similar. In experimental infections of mice, the protective action of BL-S 578 was more effective than cephalexin against Staphylococcus aureus and Streptococcus pneumoniae. BL-S 578 was more resistant than cephalexin to the beta-lactamases produced by Klebsiella pneumoniae and Escherichia coli.
D000284:Administration, Oral; D000818:Animals; D001419:Bacteria / Q000187:drug effects*; D002506:Cephalexin / Q000378:metabolism / Q000494:pharmacology; D002511:Cephalosporins / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D055598:Chemical Phenomena; D002621:Chemistry; D004353:Drug Evaluation, Preclinical; D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D007711:Klebsiella pneumoniae / Q000187:drug effects / Q000201:enzymology; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D011485:Protein Binding; D013211:Staphylococcus aureus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects; D001618:beta-Lactamases / Q000378:metabolism
D002511:Cephalosporins; D001618:beta-Lactamases; D002506:Cephalexin